NCT01464905View on ClinicalTrials.gov

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

PHASE3UnknownINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2014

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BIOLOGICAL

NU100

0.25 mg SQ, every other day for 12 months

BIOLOGICAL

Placebo

1 mL SQ, every other day for 4 months

BIOLOGICAL

rhIFN beta-1b

0.25 mg SQ, every other day for 12 months

Trial Locations (12)

Unknown

Minsk

Sofia

Zagreb

Tbilisi

Budapest

Rome

Beirut

Warsaw

Moscow

Belgrade

Barcelona

Kiev

Sponsors

Lead Sponsor

Nuron Biotech Inc.
All Listed Sponsors
lead

Nuron Biotech Inc.

INDUSTRY